-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NSn71SPbZ2929gMVbZ3Hj+DlVhw3WDgUVNTO+tKlTiHYsC3x+W9o1jkwx4Esxplt zEFiwHgt4xbS7Ni5TbyqaQ== 0001030157-02-000004.txt : 20020414 0001030157-02-000004.hdr.sgml : 20020414 ACCESSION NUMBER: 0001030157-02-000004 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020213 GROUP MEMBERS: AVENTIS PHARMACEUTICALS INC. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELL GENESYS INC CENTRAL INDEX KEY: 0000865231 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943061375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45192 FILM NUMBER: 02540043 BUSINESS ADDRESS: STREET 1: 342 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6504254400 MAIL ADDRESS: STREET 1: 342 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HMR PHARMA INC CENTRAL INDEX KEY: 0001030157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431769328 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 SC 13G/A 1 cellgen-13ga.txt CELL GENESYS 13G/A 2/02 =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 CELL GENESYS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE --------------------------------------------------------------------------- (Title of Class of Securities) 150921 10 4 ----------------- (CUSIP Number) December 31, 2001 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ x ] Rule 13d-1(c) [ ] Rule 13d-1(d) =========================================================================== - --------------------------------------------------------------------------- 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ X ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented less than 5% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ X ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented less than 5% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- This Amendment No. 2 to the Statement on Schedule 13G with respect to the Common Stock of Cell Genesys, Inc. (the "Issuer"), is filed solely to amend Item 5(e) to set forth that during the year ended December 31, 2001, Aventis Pharmaceuticals Inc., a Delaware corporation ("API"), and HMR Pharma, Inc., a Delaware corporation ("Pharma"), each ceased to be the beneficial owner of more than 5% of any class of equity securities of the Issuer. - --------------------------------------------------------------------------- ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS (e) API and Pharma each ceased to be the beneficial owner of more than 5% of any class of equity securities of the Issuer during the year ended December 31, 2001. SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. AVENTIS PHARMACEUTICALS INC. Date: February 12, 2002 By: /s/ Edward H. Stratemeier --------------------------- Edward H. Stratemeier Vice President SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. HMR PHARMA, INC. Date: February 12, 2002 By: /s/ Phillip R. Ridolfi ------------------------ Phillip R. Ridolfi President -----END PRIVACY-ENHANCED MESSAGE-----